XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Licensing, Acquisitions and Other Arrangements (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Feb. 28, 2022
Collaborative and license agreements          
Cash outflows related to acquisitions and investments     $ (513) $ (394)  
Acquired IPR&D and milestones $ 280 $ 269 430 414  
Gain on divestitures       172  
Collaborative arrangement          
Collaborative and license agreements          
Research and development milestone expenses 60 47 78 62  
Syndesi | Collaborative arrangement          
Collaborative and license agreements          
Acquired IPR&D and milestones   130      
Syndesi | Collaborative arrangement | Maximum          
Collaborative and license agreements          
Potential payments under agreement certain milestones         $ 870
Juvise Pharmaceuticals | Other operating income (expense)          
Collaborative and license agreements          
Gain on divestitures   172      
Juvise Pharmaceuticals | Collaborative arrangement          
Collaborative and license agreements          
Proceeds from sale of assets   215      
Other Collaboration Arrangements | Collaborative arrangement          
Collaborative and license agreements          
Acquired IPR&D and milestones $ 220 $ 222 $ 352 $ 222